BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Troldborg A, Jensen L, Deleuran B, Stengaard-Pedersen K, Thiel S, Jensenius JC. The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus. Front Immunol 2018;9:581. [PMID: 29632534 DOI: 10.3389/fimmu.2018.00581] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
2 Troldborg A, Jensenius JC. C3dg Quantification by PEG Precipitation and or TRIFMA. Methods Mol Biol 2021;2227:43-9. [PMID: 33847929 DOI: 10.1007/978-1-0716-1016-9_4] [Reference Citation Analysis]
3 Rong C, Xu H, Yan C, Wei F, Zhou H, Guan X. Linc8986 and linc0597 in plasma are novel biomarkers for systemic lupus erythematosus. Exp Ther Med 2021;22:1210. [PMID: 34584555 DOI: 10.3892/etm.2021.10644] [Reference Citation Analysis]
4 Jensen TS, Opstrup KV, Christiansen G, Rasmussen PV, Thomsen ME, Justesen DL, Schønheyder HC, Lausen M, Birkelund S. Complement mediated Klebsiella pneumoniae capsule changes. Microbes Infect 2020;22:19-30. [PMID: 31473336 DOI: 10.1016/j.micinf.2019.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Halkjær L, Troldborg A, Pedersen H, Jensen L, Hansen AG, Hansen TK, Bjerre M, Østergaard JA, Thiel S. Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans. Front Immunol 2020;11:774. [PMID: 32431705 DOI: 10.3389/fimmu.2020.00774] [Reference Citation Analysis]
6 Weinstein A, Alexander RV, Zack DJ. A Review of Complement Activation in SLE. Curr Rheumatol Rep 2021;23:16. [PMID: 33569681 DOI: 10.1007/s11926-021-00984-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Troldborg A, Thiel S, Mistegaard CE, Hansen A, Korsholm TL, Stengaard-Pedersen K, Loft AG. Plasma levels of H- and L-ficolin are increased in axial spondyloarthritis: improvement of disease identification. Clin Exp Immunol 2020;199:79-87. [PMID: 31518441 DOI: 10.1111/cei.13374] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Heesterbeek TJ, Lechanteur YTE, Lorés-Motta L, Schick T, Daha MR, Altay L, Liakopoulos S, Smailhodzic D, den Hollander AI, Hoyng CB, de Jong EK, Klevering BJ. Complement Activation Levels Are Related to Disease Stage in AMD. Invest Ophthalmol Vis Sci 2020;61:18. [PMID: 32176267 DOI: 10.1167/iovs.61.3.18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
9 Kim AHJ, Strand V, Sen DP, Fu Q, Mathis NL, Schmidt MJ, Bruchas RR, Staten NR, Olson PK, Stiening CM, Atkinson JP. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity. Arthritis Rheumatol 2019;71:420-30. [PMID: 30294950 DOI: 10.1002/art.40747] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
10 Tan G, Baby B, Zhou Y, Wu T. Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus. Front Immunol 2021;12:808839. [PMID: 35095896 DOI: 10.3389/fimmu.2021.808839] [Reference Citation Analysis]
11 Nygaard A, Hendricks O, Loft AG, Christiansen AA, Brandslund I, Jurik AG, Schiøttz-Christensen B. Complement C3d is not associated with axial spondyloarthritis and magnetic resonance imaging changes at the sacroiliac joint. Scand J Rheumatol 2021;:1-8. [PMID: 34470588 DOI: 10.1080/03009742.2021.1946255] [Reference Citation Analysis]
12 Zhang L, Kwak H, Yin S, Lee B, Chang Y, Hahn M, Yang J, Lee J, Park Y. An OMICS-based study of the role of C3dg in keratinocytes: RNA sequencing, antibody-chip array, and bioinformatics approaches. International Journal of Biological Macromolecules 2019;133:391-411. [DOI: 10.1016/j.ijbiomac.2019.04.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Troldborg A, Halkjær L, Pedersen H, Hansen A, Loft AG, Lindegaard H, Stengaard-Pedersen K, Graversen JH, Palarasah Y, Thiel S. Complement activation in human autoimmune diseases and mouse models; employing a sandwich immunoassay specific for C3dg. J Immunol Methods 2020;486:112866. [PMID: 32941885 DOI: 10.1016/j.jim.2020.112866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Kim BJ, Mastellos DC, Li Y, Dunaief JL, Lambris JD. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Prog Retin Eye Res 2021;83:100936. [PMID: 33321207 DOI: 10.1016/j.preteyeres.2020.100936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Emre C, Do KV, Jun B, Hjorth E, Alcalde SG, Kautzmann MI, Gordon WC, Nilsson P, Bazan NG, Schultzberg M. Age-related changes in brain phospholipids and bioactive lipids in the APP knock-in mouse model of Alzheimer's disease. Acta Neuropathol Commun 2021;9:116. [PMID: 34187579 DOI: 10.1186/s40478-021-01216-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Cabezas-Falcon S, Norbury AJ, Hulme-Jones J, Klebe S, Adamson P, Rudd PA, Mahalingam S, Ong LC, Alonso S, Gordon DL, Carr JM. Changes in complement alternative pathway components, factor B and factor H during dengue virus infection in the AG129 mouse. J Gen Virol 2021;102. [PMID: 33410734 DOI: 10.1099/jgv.0.001547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]